Methods for detecting ovarian cancer
AssigneeZora Biosciences Oy
InventorMika Hilvo
Life of this patent
Estimating the term…
Abstract
The present description is related to the field of ovarian cancer diagnostics. It introduces novel biomarkers that can be used to detect presence of ovarian cancer and to provide a prognosis of the disease.
Claims36
An in vitro screening method for assessing whether a subject is at risk to develop or is suffering from ovarian cancer, comprising:
- assaying a sample from said subject to determine a concentration of at least one small molecule biomarker, wherein an increase or decrease in the concentration of the at least one small molecule biomarker in said sample, when compared to a control sample, is indicative of said subject suffering from or having an increased risk of developing ovarian cancer;
- (1) wherein the at least one small molecule biomarker whose increase in concentration is compared to the control is a dihydroxybutyric acid and/or a trihydroxybutyric acid;
- (2) wherein the at least one small molecule biomarker whose decrease in concentration is compared to the control is a sphingomyelin;
- (3) wherein the at least one small molecule biomarker whose increase in concentration is compared to the control is a long chain triglyceride having acyl side chains comprising at least 54 carbon atoms in total;
- (4) wherein the at least one small molecule biomarker whose decrease in concentration is compared to the control is a triglyceride having acyl side chains comprising less than 54 carbon atoms in total;
- and/or
- (5) wherein the at least one small molecule biomarker whose increase in concentration is compared to the control is adipic acid.
A method of assessing whether a subject has a decreased survival prognosis for ovarian cancer, comprising:
- measuring the level of at least one small molecule biomarker in a sample from the subject,
- wherein an increase in the level of the at least one small molecule biomarker, relative to the level of the corresponding small molecule biomarker in a control sample, is indicative that the subject has a poor survival prognosis for the ovarian cancer, and wherein the at least one small molecule biomarker is a dihydroxybutyric acid, a trihydroxybutyric acid, a hydroxyacid, an adipic acid, a hydroxybutyric acid, and/or ketone bodies;
- and/or
- wherein a decrease in the level of the at least one small molecule biomarker, relative to the level of the corresponding small molecule biomarker in a control sample, is indicative that the subject has a poor survival prognosis for the ovarian cancer, and wherein the at least one small molecule biomarker is a sphingomyelin.
An in vitro method for assessing success rate of an ovarian cancer tumor removal in a subject comprising measuring a concentration of at least one small molecule biomarker in a sample from the subject, wherein an increase or decrease in the concentration of the at least one small molecule biomarker, relative to the concentration of the corresponding small molecule biomarker in a control sample, is indicative that the tumor removal was successful, and
- (1) wherein the at least one small molecule biomarker whose decrease in concentration is compared to the control is a dihydroxybutyric acid and/or a trihydroxybutyric acid;
- (2) wherein the at least one small molecule biomarker whose increase in concentration is compared to the control is a sphingomyelin;
- (3) wherein the at least one small molecule biomarker whose decrease in concentration is compared to the control is a long chain triglyceride having acyl side chains comprising at least 54 carbon atoms in total;
- (4) wherein the at least one small molecule biomarker whose increase in concentration is compared to the control is a triglyceride having acyl side chains comprising less than 54 carbon atoms in total;
- and/or
- (5) wherein the at least one small molecule biomarker whose decrease in concentration is compared to the control is adipic acid.
An in vitro method of evaluating effectiveness of an ovarian cancer therapy in a subject, comprising:
- assaying a sample from said subject to determine a concentration of at least one first small molecule biomarker and/or a concentration of at least one second small molecule biomarker, wherein an increase or decrease in concentration of the at least one first small molecule biomarker and/or second small molecule biomolecule in said sample, when compared to a control sample, is indicative of effectiveness of said ovarian cancer therapy;
- (1) wherein the at least one first small molecule biomarker whose concentration is compared to the control is a dihydroxybutyric and/or a trihydroxybutyric acid;
- (2) wherein the at least one first small molecule biomarker whose concentration is compared to the control is a sphingomyelin;
- (3) wherein the at least one first small molecule biomarker whose concentration is compared to the control is a long chain triglyceride having acyl side chains comprising at least 54 carbon atoms in total;
- (4) wherein the at least one first small molecule biomarker whose concentration is compared to the control is a triglyceride having acyl side chains comprising less than 54 carbon atoms in total;
- and/or
- (5) wherein the at least one first small molecule biomarker whose concentration is compared to the control is adipic acid;
- and/or
- (a) wherein the at least one second small molecule biomarker whose concentration is compared to the control is a dihydroxyacid and/or an adipic acid;
- and/or
- (b) wherein the at least one second small molecule biomarker whose concentration is compared to the control is a hydroxybutyric acid and/or ketone bodies;
- and wherein said increase in at least one of (1), (3), (5), (a), and (b), or decrease in (2) and/or (4), is indicative of ineffective treatment;
- and/or
- decrease in at least one of (1), (3), (5), (a), and (b), or increase in (2) and/or (4), is indicative of effective treatment.
An in vitro method of determining concentration of a metabolite in ovarian tissue of a subject, comprising:
- assaying a blood sample obtained from the subject to determine a concentration of the metabolite;
- comparing the concentration of the metabolite with a concentration in a control sample wherein an increase in a level of the metabolite compared to the control sample is indicative that the subject has increased concentration of the metabolite in ovarian tissue;
- and wherein the metabolite is 3 hydroxybutyric acid, 2-hydroxybutyric acid, 3,4-dihydroxybutyric acid, SM(d18:1/21:0), SM(d18:1/14:0), adipic acid, 4-hydroxyphenyllactic acid, 2,4-dihydroxybutyric acid, 3-hydroxyisovaleric acid, and/or 2,3-dihydroxybutyric acid.
An in vitro screening method for assessing whether a subject is at risk to develop or is suffering from ovarian cancer comprising assaying a breath of the subject to determine a concentration of acetone in the breath, wherein an increase in the concentration of acetone in the breath when compared to a control sample is indicative of said subject suffering from or having an increased risk of developing ovarian cancer.
Dependencies are inferred from the claim text.